As our use of new MS drugs progresses, real-world evidence starts becoming available that usefully complements trials-derived knowledge. Beyond informing us on how to best move from one drug to another one, it can also refine our understanding of the longer-term consequences of the treatment choices we pose today and help us best tailoring drug choices to individual patient needs. To discuss these key elements, we have here a panel of experts who will complement mechanistic and trial considerations with their own extensive experiences, in order to share useable and practical advices and tips.
Dermatology
Geaccrediteerd voor artsen (N° 25034524 - 1 punt)
Rhumatology & Orthopedy
Geaccrediteerd voor artsen (N° - punt)
Dermatology ...
Geaccrediteerd voor artsen (N° 25019731 - 1.5 punten)
Geaccrediteerd voor artsen - 25034524 - 1CP